0.7298

0.38% -0.0028

Cognition Therapeutics Inc (CGTX)

Overview News Price History Financials Discussions Forecast

Cognition Therapeutics Inc stock is traded at $0.7298, with a volume of 420.60K. It is down -0.38% in the last 24 hours and down -28.45% over the past month. Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Previous Close:

$0.7326

Open:

$0.76

24h Volume:

420.60K

Relative Volume:

0.56

Market Cap:

$69.40M

Revenue:

Net Income/Loss:

$-19.58M

P/E Ratio:

-2.832

EPS:

-0.2577

Net Cash Flow:

$-20.25M

1W Performance:

-16.78%

1M Performance:

-28.45%

6M Performance:

-34.25%

1Y Performance:

-60.55%

1-Day Range:

$0.7134

$0.7874

1-Week Range:

$0.7134

$0.93

52-Week Range:

$0.5501

$1.9999

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name

Cognition Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

412-481-2210

Address

2500 WESTCHESTER AVE, PURCHASE

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

CGTX's Discussions on Twitter

Compare CGTX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGTX Cognition Therapeutics Inc	0.7298	69.40M	0	-19.58M	-20.25M	-0.2577
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Upgrade	B. Riley Securities	Neutral → Buy
Jul-30-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-03-21	Initiated	B. Riley Securities	Buy
Nov-03-21	Initiated	Oppenheimer	Outperform

Cognition Therapeutics Inc Stock (CGTX) Latest News

Oct 13, 2026

A drug patent runs to 2045. FDA approval may allow up to five more years. - Stock Titan

Oct 13, 2026

Oct 02, 2026

Cognition Therapeutics Stock Price Forecast. Should You Buy CGTX? - StockInvest.us

Oct 02, 2026

Sep 29, 2026

Cognition Therapeutics Schedules FDA Type C Meeting to Discuss Phase 3 Trial Endpoint for Zervimesine in Dementia with Lewy Bodies - Quiver Quantitative

Sep 29, 2026

An experimental drug slowed the progression of hallucinations and delusions by 89% vs. placebo. - Stock Titan

Sep 29, 2026

Sep 11, 2026

FDA aligns with Cognition on pivotal DLB psychosis trial - scanx.trade

Sep 11, 2026

Sep 08, 2026

An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan

Sep 08, 2026

Sep 05, 2026

MU: Micron Technology Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 05, 2026

Aug 24, 2026

Cognition (CGTX) Today: Moves 1.14% Lower to $0.98 for the Current Session; Technical Setup: the $0.93 to $1.03 Range Remains in Focus under the Current SnapshotIPO Entry Watch - vinanet.vn

Aug 24, 2026

Aug 19, 2026

Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Cognition Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026

Aug 17, 2026

HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat

Aug 17, 2026

Aug 16, 2026

Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn

Aug 16, 2026

Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Money Flow Index - dars.gov.et

Aug 16, 2026

Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Point of Control - careplusvn.com

Aug 16, 2026

Aug 15, 2026

Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 12, 2026

CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat

Aug 12, 2026

Aug 08, 2026

Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative

Aug 08, 2026

Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 07, 2026